Clinical outcomes of ALK+ non-small cell lung cancer in Denmark

References

• Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013;19(15):4273–4281. doi: 10.1158/1078-0432.CCR-13-0318.
   PubMed Web of Science ®Google Scholar
• Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14(13):4275–4283. doi: 10.1158/1078-0432.CCR-08-0168.
   PubMed Web of Science ®Google Scholar
• Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115(8):1723–1733. doi: 10.1002/cncr.24181.
   PubMed Web of Science ®Google Scholar
• Cognigni V, Pecci F, Lupi A, et al. The landscape of ALK-rearranged non-small cell lung cancer: a comprehensive review of clinicopathologic, genomic characteristics, and therapeutic perspectives. Cancers (Basel). 2022;14(19):4765. doi: 10.3390/cancers14194765.
   PubMed Web of Science ®Google Scholar
• Pacheco JM, Camidge DR. Is long-term survival possible for patients with stage IV ALK + non-small cell lung cancer? Expert Rev Respir Med. 2019;13(5):399–401. doi: 10.1080/17476348.2019.1596028.
   PubMed Web of Science ®Google Scholar
• Britschgi C, Addeo A, Rechsteiner M, et al. Real-world treatment patterns and survival outcome in advanced anaplastic lymphoma kinase (ALK) rearranged non-small-cell lung cancer patients. Front Oncol. 2020;10:1299. doi: 10.3389/fonc.2020.01299.
   PubMed Web of Science ®Google Scholar
• Duruisseaux M, Besse B, Cadranel J, et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget. 2017;8(13):21903–21917. doi: 10.18632/oncotarget.15746.
   PubMedGoogle Scholar
• Pacheco JM, Gao D, Smith D, et al. Natural history and factors associated with overall survival in stage IV ALK-rearranged non-small cell lung cancer. J Thorac Oncol. 2019;14(4):691–700. doi: 10.1016/j.jtho.2018.12.014.
   PubMed Web of Science ®Google Scholar
• Gibson AJW, Box A, Dean ML, et al. Retrospective real-world outcomes for patients with ALK-rearranged lung cancer receiving ALK receptor tyrosine kinase inhibitors. JTO Clin Res Rep. 2021;2(4):100157. doi: 10.1016/j.jtocrr.2021.100157.
   PubMedGoogle Scholar
• Lauppe R, Nilsson FOL, Fues Wahl H, et al. Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration: a Swedish nationwide retrospective study. Acta Oncol. 2022;61:(11):1354–1361.
   PubMed Web of Science ®Google Scholar
• Patel A, Batra U, Prasad KT, et al. Real-world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: a multicenter study from India. Curr Probl Cancer. 2020;44(3):100571. doi: 10.1016/j.currproblcancer.2020.100571.
   PubMed Web of Science ®Google Scholar
• Tsimafeyeu I, Moiseenko F, Orlov S, et al. Overall survival of patients with ALK-positive metastatic non-small-cell lung cancer in the Russian Federation: nationwide cohort study. J Glob Oncol. 2019;5:1–7. doi: 10.1200/JGO.19.00024.
   PubMed Web of Science ®Google Scholar
• Melchior L, Santoni-Rugiu E, Sørensen J, et al. EP1.08-07 correlation between genetic profiling and response in danish ALK-positive NSCLC patients treated with crizotinib. J Thorac Oncol. 2019;14:S997–S998.
   Web of Science ®Google Scholar
• Waterhouse DM, Espirito JL, Chioda MD, et al. Retrospective observational study of ALK-inhibitor therapy sequencing and outcomes in patients with ALK-positive non-small cell lung cancer. Drugs Real World Outcomes. 2020;7(4):261–269. doi: 10.1007/s40801-020-00207-6.
   PubMedGoogle Scholar
• Schmid S, Cheng S, Chotai S, et al. Real-world treatment sequencing, toxicities, health utilities, and survival outcomes in patients with advanced ALK-rearranged non-small-cell lung cancer. Clin Lung Cancer. 2023;24(1):40–50. doi: 10.1016/j.cllc.2022.09.007.
   PubMed Web of Science ®Google Scholar
• Eide IJZ, Nilssen Y, Stensland EM, et al. Real-world data on EGFR and ALK testing and TKI usage in Norway-a nation-wide population study. Cancers (Basel). 2023;15(5):1505. doi: 10.3390/cancers15051505.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018;379(21):2027–2039. doi: 10.1056/NEJMoa1810171.
   PubMed Web of Science ®Google Scholar
• Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829–838. doi: 10.1056/NEJMoa1704795.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370(13):1189–1197. doi: 10.1056/NEJMoa1311107.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018–2029. doi: 10.1056/NEJMoa2027187.
   PubMed Web of Science ®Google Scholar